Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Conditions:   Recurrent Head and Neck Squamous Cell Carcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Pembrolizumab;   Drug: Epacadostat;   Drug: Cetuximab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: 5-Fluorouracil
Sponsors:   Incyte Corporation;   Merck Sharp & Dohme Corp.
Not yet recruiting

http://ift.tt/2isbzDC